A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Dermatitis, Atopic
In brief
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.
Key facts
- Study ID
- NCT07604324
- Run by
- Novartis Pharmaceuticals
- People needed
- 63
- Starts
- 2026-06-02
- Expected to finish
- 2028-01-28
- Last updated by the study team
- 2026-07-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Novartis Investigative Site — Fukuoka, Japan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.